文献速递肿瘤 PET/CT

淋巴瘤患者基线18F-FDG PET/CT总代谢肿瘤体积测量的国际基准:迈向临床实施的里程碑

International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline 18F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation.
PubMed 文献 · J Nucl Med · 2024-09-03

本研究建立了淋巴瘤患者基线18F-FDG PET/CT总代谢肿瘤体积(TMTV)的标准化基准数据集,由12名核医学专家使用LIFEx或ACCURATE软件对60例(滤泡性、霍奇金、弥漫大B细胞淋巴瘤各20例)进行分步测量。最终TMTV4在87%的病例中读者间差异小于10%或小于10 cm3,70%的病例TMTV4等于TMTV1无需额外交互。作者认为该分割方法高度可重复,但弥漫性脾摄取纳入与否需按淋巴瘤亚型定义标准。

要点

  • TMTV4在87%的病例中读者间差异小于10%或小于10 cm3。
  • 70%的病例TMTV4等于TMTV1,无需额外读者交互。
  • 5例TMTV差异大于25%源于对弥漫性脾摄取纳入的分歧。

核心结论

  • 所提出的分割方法使TMTV测量高度可重复,70%的患者仅需极少读者交互。
  • 弥漫性脾摄取的纳入或排除需根据淋巴瘤亚型定义具体标准。
  • 公开的基准数据集允许比较研究结果,并可作为测试其他分割方法改进的参考。

研究设计与样本

  • 研究纳入60例基线18F-FDG PET/CT扫描,包括20例滤泡性淋巴瘤、20例霍奇金淋巴瘤和20例弥漫大B细胞淋巴瘤。
  • 由12名核医学专家测量TMTV,每名专家分析20例,每个病例由3-4名读者处理,根据读者偏好选择LIFEx或ACCURATE软件。
  • 分析分步进行:TMTV1自动预选病灶(SUV至少4且体积至少3 cm3,单击去除生理性摄取);TMTV2额外单击去除反应性骨髓和脾;TMTV3手动编辑去除其他生理性摄取(如需要);TMTV4可选单击添加病灶(SUV至少4,无体积阈值)。

主要发现

  • 最终TMTV(TMTV4)范围为8至2,288 cm3。
  • 所有读者间在87%的病例(52/60)中一致性极好,差异小于10%或小于10 cm3。
  • 70%的病例中TMTV4等于TMTV1,无需额外读者交互。
  • TMTV4的差异仅与读者对病灶纳入或生理性高摄取区域去除的解释有关,与软件选择无关。
  • 5例TMTV差异大于25%是由于对弥漫性脾摄取纳入的分歧。

关键数值与推荐

  • TMTV1自动预选病灶采用SUV至少4和体积至少3 cm3的阈值。
  • TMTV4可选添加病灶采用SUV至少4、无体积阈值。
  • 读者间一致性极好定义为差异小于10%或小于10 cm3。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Total metabolic tumor volume (TMTV) is prognostic in lymphoma. However, cutoff values for risk stratification vary markedly, according to the tumor delineation method used. We aimed to create a standardized TMTV benchmark dataset allowing TMTV to be tested and applied as a reproducible biomarker. Methods: Sixty baseline 18F-FDG PET/CT scans were identified with a range of disease distributions (20 follicular, 20 Hodgkin, and 20 diffuse large B-cell lymphoma). TMTV was measured by 12 nuclear medicine experts, each analyzing 20 cases split across subtypes, with each case processed by 3-4 readers. LIFEx or ACCURATE software was chosen according to reader preference. Analysis was performed stepwise: TMTV1 with automated preselection of lesions using an SUV of at least 4 and a volume of at least 3 cm3 with single-click removal of physiologic uptake; TMTV2 with additional removal of reactive bone marrow and spleen with single clicks; TMTV3 with manual editing to remove other physiologic uptake, if required; and TMTV4 with optional addition of lesions using mouse clicks with an SUV of at least 4 (no volume threshold). Results: The final TMTV (TMTV4) ranged from 8 to 2,288 cm3, showing excellent agreement among all readers in 87% of cases (52/60) with a difference of less than 10% or less than 10 cm3 In 70% of the cases, TMTV4 equaled TMTV1, requiring no additional reader interaction. Differences in the TMTV4 were exclusively related to reader interpretation of lesion inclusion or physiologic high-uptake region removal, not to the choice of software. For 5 cases, large TMTV differences (>25%) were due to disagreement about inclusion of diffuse splenic uptake. Conclusion: The proposed segmentation method enabled highly reproducible TMTV measurements, with minimal reader interaction in 70% of the patients. The inclusion or exclusion of diffuse splenic uptake requires definition of specific criteria according to lymphoma subtype. The publicly available proposed benchmark allows comparison of study results and could serve as a reference to test improvements using other segmentation approaches.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Boellaard R, Buvat I, Nioche C, et al. International Benchmark for Total Metabolic Tumor Volume Measurement in Baseline 18F-FDG PET/CT of Lymphoma Patients: A Milestone Toward Clinical Implementation. J Nucl Med. 2024. PMID: 39089812. doi:10.2967/jnumed.124.267789

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。